Dr. George J. Chang, MD

Dr. Chang practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Chang's NPI, 1295820496, was assigned on October 4, 2006. Dr. Chang graduated from David Geffen School of Medicine at UCLA in 1995. Dr. Chang holds Texas license M0036.

Dr. Chang's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Chang's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chang practices. Vendor and product names are available with a free account.

Colon and rectal surgery is Dr. Chang's primary specialty in the NPI Registry, under taxonomy code 208C00000X. Dr. Chang is board certified in colon & rectal surgery by the American Board of Colon and Rectal Surgery. Dmand AI has Dr. Chang's licenses on file in 12 states: Texas, Florida, Arizona, California, Georgia, Oklahoma, Alabama, Louisiana, Mississippi, Tennessee, Washington and Minnesota.

Dmand AI lists colonoscopy and colon removal among the conditions Dr. Chang treats.

CMS data shows 15 Medicare services from Dr. Chang across 1 procedure code in 2024, for 62 Medicare patients. Medicare paid $578 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 62 Medicare patients who saw Dr. Chang in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chang's median patient age at 69, with 48% women.

In 2024, Dr. Chang wrote 25 Medicare Part D claims. 96% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Chang for performance year 2024, reported as part of a group. Dr. Chang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chang as offering telehealth. CMS counts 31 procedures of colonoscopy by Dr. Chang, more than 54% of the clinicians it reports for that procedure.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 361 papers to Dr. Chang, published from 2004 to 2025. 2020 was the busiest year, with 27. The most frequent topics are Rectal Neoplasms, Colorectal Neoplasms and Neoadjuvant Therapy. Dr. Chang has published most often in Ann Surg Oncol. Dr. Chang's most frequent co-authors are John M. Skibber, MD, Brian K. Bednarski, MD and Prajnan Das, MD, MPH.

Dmand AI links Dr. Chang to 9 clinical trials. 5 are still active or recruiting. Conditions studied include Rectal Diseases, Rectal Neoplasms and Colorectal Neoplasms. M.D. Anderson Cancer Center sponsors the most, 5.

CMS Open Payments shows 71 general payments to Dr. Chang from 12 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 60% of the total. Medtronic, Inc. paid the most, $9,590.

Dmand AI lists 3 awards for Dr. Chang.

Dr. Chang graduated from David Geffen School of Medicine at UCLA in 1995. Dr. Chang is a member of ACS, ASCO, ASCRS, American Surgical Association, AAS and SSO.

Dr. Chang is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.